title: Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.
abstract: A hallmark of metastasis is organ specificity; however, little is known about the underlying signaling pathways responsible for the colonization and growth of tumor cells in target organs. Since tyrosine kinase receptor activation is frequently associated with prostate cancer progression, we have investigated the role of a common signaling intermediary, activated Ras, in prostate cancer metastasis. Three effector pathways downstream of Ras, Raf/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase, and Ral guanine nucleotide exchange factors (RalGEFs), were assayed for their ability to promote the metastasis of a tumorigenic, nonmetastatic human prostate cancer cell line, DU145. Oncogenic Ras promoted the metastasis of DU145 to multiple organs, including bone and brain. Activation of the Raf/ERK pathway stimulated metastatic colonization of the brain, while activation of the RalGEF pathway led to bone metastases, the most common organ site for prostate cancer metastasis. In addition, loss of RalA in the metastatic PC3 cell line inhibited bone metastasis but did not affect subcutaneous tumor growth. Loss of Ral appeared to suppress expansive growth of prostate cancer cells in bone, whereas homing and initial colonization were less affected. These data extend our understanding of the functional roles of the Ral pathway and begin to identify signaling pathways relevant for organ-specific metastasis.
authors: Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, 37 Convent Dr., Rm. 1068, Bethesda, MD 20892, USA.
authors: JuanJuan
authors: J
authors: Yin
authors: Claire
authors: C
authors: Pollock
authors: Kirsten
authors: K
authors: Tracy
authors: Monika
authors: M
authors: Chock
authors: Philip
authors: P
authors: Martin
authors: Michael
authors: M
authors: Oberst
authors: Kathleen
authors: K
authors: Kelly
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000098:blood supply / Q000473:pathology / Q000556:secondary*; D001932:Brain Neoplasms / Q000098:blood supply / Q000473:pathology / Q000556:secondary; D045744:Cell Line, Tumor; D011905:Genes, ras; D006801:Humans; D008297:Male; D051379:Mice; D050505:Mutant Proteins / Q000378:metabolism; D009928:Organ Specificity; D011471:Prostatic Neoplasms / Q000473:pathology*; D015398:Signal Transduction; D020725:ral GTP-Binding Proteins / Q000378:metabolism*; D020726:ral Guanine Nucleotide Exchange Factor / Q000378:metabolism*; D018631:ras Proteins / Q000378:metabolism
chemical_list: D050505:Mutant Proteins; C483163:Ralb protein, human; D020726:ral Guanine Nucleotide Exchange Factor; C492198:RALA protein, human; D020725:ral GTP-Binding Proteins; D018631:ras Proteins
references: Cancer. 1997 Oct 15;80(8 Suppl):1572-80
references: 9362424
references: Curr Biol. 2006 Dec 19;16(24):2385-94
references: 17174914
references: J Surg Oncol. 1998 Apr;67(4):255-60
references: 9579374
references: J Urol. 1998 Sep;160(3 Pt 1):932-6
references: 9720590
references: Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2122-8
references: 10051605
references: Cancer Res. 1999 Apr 15;59(8):1987-93
references: 10213511
references: Trends Cell Biol. 2004 Nov;14(11):639-47
references: 15519853
references: J Clin Invest. 2005 Jan;115(1):44-55
references: 15630443
references: Nat Rev Cancer. 2005 Jan;5(1):21-8
references: 15630412
references: Surg Oncol Clin N Am. 2001 Apr;10(2):357-81, ix-x
references: 11382592
references: Mol Cell Biol. 2001 Sep;21(17):5958-69
references: 11486034
references: Trends Cell Biol. 2001 Nov;11(11):S44-51
references: 11684442
references: Nat Cell Biol. 2002 Jan;4(1):66-72
references: 11740492
references: Nature. 2002 Jan 31;415(6871):530-6
references: 11823860
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250
references: Nat Rev Cancer. 2002 Aug;2(8):563-72
references: 12154349
references: Nat Rev Cancer. 2002 Aug;2(8):584-93
references: 12154351
references: Nature. 2002 Aug 22;418(6900):823
references: 12192390
references: Nat Genet. 2003 Jan;33(1):49-54
references: 12469122
references: Cancer Res. 2003 Apr 15;63(8):1981-9
references: 12702592
references: Nat Genet. 2003 May;34(1):23; author reply 25
references: 12721548
references: Nat Rev Cancer. 2003 Jun;3(6):453-8
references: 12778135
references: Cancer Cell. 2003 Jun;3(6):537-49
references: 12842083
references: N Engl J Med. 2003 Jul 24;349(4):366-81
references: 12878745
references: Trends Cell Biol. 2003 Aug;13(8):419-25
references: 12888294
references: EMBO Rep. 2003 Aug;4(8):800-6
references: 12856001
references: J Cell Biochem. 2004 Jan 1;91(1):13-25
references: 14689577
references: Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51
references: 15014901
references: Biochem Soc Trans. 2004 Jun;32(Pt3):397-402
references: 15157146
references: Mol Cell Biol. 2004 Jul;24(13):5746-56
references: 15199131
references: Int J Cancer. 1978 Mar 15;21(3):274-81
references: 631930
references: Am J Pathol. 1980 Oct;101(1):101-13
references: 7446696
references: Clin Exp Metastasis. 1992 May;10(3):191-9
references: 1582089
references: Cell. 1995 Feb 24;80(4):533-41
references: 7867061
references: Mol Cell Biol. 1995 Aug;15(8):4578-84
references: 7623849
references: Cell. 1997 May 2;89(3):457-67
references: 9150145
references: EMBO J. 2005 Jan 12;24(1):54-62
references: 15592429
references: Cancer Cell. 2005 Mar;7(3):219-26
references: 15766660
references: Cancer Cell. 2005 Jun;7(6):533-45
references: 15950903
references: Nature. 2005 Jul 28;436(7050):518-24
references: 16049480
references: Cancer Res. 2005 Aug 15;65(16):7111-20
references: 16103060
references: Mol Cancer Ther. 2006 Nov;5(11):2606-12
references: 17088437
references: Clin Chem. 1998 Apr;44(4):705-23
references: 9554481